153566-63-3

Basic information

• Product Name: 3-Pyrrolidineacetonitrile, 1-[(1S)-1-phenylethyl]-, (3R)-
• CAS NO: 153566-63-3
• Molecular Formula: C14H18N2
• Molecular Weight: 214.31
• Mol File: 153566-63-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-Pyrrolidineacetonitrile, 1-[(1S)-1-phenylethyl]-, (3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyrrolidineacetonitrile, 1-[(1S)-1-phenylethyl]-, (3R)-(153566-63-3)
• EPA Substance Registry System: 3-Pyrrolidineacetonitrile, 1-[(1S)-1-phenylethyl]-, (3R)-(153566-63-3)

Safety Data

• Hazardous Substances Data: 153566-63-3(Hazardous Substances Data)

Upstream product

• 173340-19-7 (3S)-1-((S)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 
• 618-36-0 rac-methylbenzylamine 
• 97-65-4 2-methylenesuccinic acid 
• 173724-95-3 (S)-1-((S)-1-phenylethyl)-3-hydroxymethylpyrrolidine 
• 508201-49-8 (3S)-1-[(S)-1-phenethyl]-3-(chloromethyl) pyrrolidine 
• 773837-37-9 sodium cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 174676-79-0 methyl (3R,1'S)-<1-(1'-phenyleth-1'-yl)-pyrrolidin-3-yl> acetate 

Relevant articles and documents

Preparation of novel azabicyclic amines and α7 nicotinic acetylcholine receptor activity of derived aryl amides

(Chemical Equation Presented) Three new azabicyclic amines, namely exo-3-amino-1-azabicyclo[3.2.1]octane, 3-amino-1-azabicyclo-[3.2.2]nonane and exo-6-amino-8-azabicyclo[3.2.1]octane, have been designed and prepared as isosteres of 3-aminoquinuclidine. Ar

1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY

The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

Substituted-aryl compounds for treatment of disease

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.